Page 675 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 40 Thalassemia Syndromes 570.e7

304. Kremastinos DT, Tiniakos G, Theodorakis GN, et al: Myocarditis in 328. Kreimer-Birnbaum M, Rusnak PA, Bannerman RM, et al: Urinary
beta-thalassemia major. A cause of heart failure. Circulation 91:66, pyrrole pigments in thalassemia and unstable hemoglobin diseases. Ann
1995. N Y Acad Sci 232:283, 1974.
305. Cohen AR, Martin M, Schwartz E: Current treatment of Cooley’s 329. Quinn CT, Johnson VL, Kim HY, et al: Renal dysfunction in patients
anemia. Intravenous chelation therapy. Ann N Y Acad Sci 612:286, with thalassaemia. Br J Haematol 153:111, 2011.
1990. 330. Cohen A, Markenson AL, Schwartz E: Transfusion requirements and
306. Davis BA, Porter JB: Long-term outcome of continuous 24-hour splenectomy in thalassemia major. J Pediatr 97:100, 1980.
deferoxamine infusion via indwelling intravenous catheters in high-risk 331. Modell B: Total management of thalassaemia major. Arch Dis Child
beta-thalassemia. Blood 95:1229, 2000. 52:489, 1977.
307. Hershko C, Konijn AM, Nick HP, et al: ICL670A: a new synthetic 332. Laopodis V, Kritikos E, Rizzoti L, et al: Laparoscopic splenectomy in
oral chelator: evaluation in hypertransfused rats with selective radioiron beta-thalassemia major patients. Advantages and disadvantages. Surg
probes of hepatocellular and reticuloendothelial iron stores and in iron- Endosc 12:944, 1998.
loaded rat heart cells in culture. Blood 97:1115, 2001. 333. de Montalembert M, Girot R, Revillon Y, et al: Partial splenectomy in
308. Eleftheriou P, Tanner M, Pennell D, et al: Response of myocardial homozygous beta thalassaemia. Arch Dis Child 65:304, 1990.
T2* to oral deferasirox monotherapy for 1 Year in 29 Patients with 334. al-Salem AH, al-Dabbous I, Bhamidibati P: The role of partial splenec-
transfusion-dependent anaemias; A subgroup analysis. Haematologica tomy in children with thalassemia. Eur J Pediatr Surg 8:334, 1998.
91:366, 2006. 335. Banani SA: Partial dearterialization of the spleen in thalassemia major.
309. Porter J, Tanner M, Pennell DJ, et al: Improved myocardial T2* in J Pediatr Surg 33:449, 1998.
transfusion dependent anemias. Blood 106:3600, 2005. 336. Pringle KC, Spigos DG, Tan WS, et al: Partial splenic embolization in
310. Neufeld EJ: Oral chelators deferasirox and deferiprone for transfusional the management of thalassemia major. J Pediatr Surg 17:884, 1982.
iron overload in thalassemia major: new data, new questions. Blood 337. Pinca A, Di Palma A, Soriani S, et al: Effectiveness of partial splenic
107:3436, 2006. embolization as treatment for hypersplenism in thalassaemia major: a
311. Mariotti E, Angelucci E, Agostini A, et al: Evaluation of cardiac status 7-year follow up. Eur J Haematol 49:49, 1992.
in iron-loaded thalassaemia patients following bone marrow transplan- 338. Stanley P, Shen TC: Partial embolization of the spleen in patients with
tation: improvement in cardiac function during reduction in body iron thalassemia. J Vasc Interv Radiol 6:137, 1995.
burden. Br J Haematol 103:916, 1998. 339. Ikeda M, Sekimoto M, Takiguchi S, et al: High incidence of thrombosis
312. Koerner MM, Tenderich G, Minami K, et al: Heart transplantation for of the portal venous system after laparoscopic splenectomy: a prospec-
end-stage heart failure caused by iron overload. Br J Haematol 97:293, tive study with contrast-enhanced CT scan. Ann Surg 241:208, 2005.
1997. 340. Singer DB: Postsplenectomy sepsis. Perspect Pediatr Pathol 1:285,
313. Perrimond H, Michel G, Orsini A, et al: First report of a cardiac 1973.
transplantation in a patient with thalassaemia major. Br J Haematol 341. Ammann AJ, Addiego J, Wara DW, et al: Polyvalent pneumococcal-
78:467, 1991. polysaccharide immunization of patients with sickle-cell anemia and
314. Olivieri NF, Liu PP, Sher GD, et al: Brief report: combined liver and patients with splenectomy. N Engl J Med 297:897, 1977.
heart transplantation for end-stage iron-induced organ failure in an 342. Ambrosino DM, Molrine DC: Critical appraisal of immunization
adult with homozygous beta-thalassemia. N Engl J Med 330:1125, strategies for prevention of infection in the compromised host. Hematol
1994. Oncol Clin North Am 7:1027, 1993.
315. Stanfield J: Acute benign pericarditis in thalassemia major. Proc R Soc 343. Borgna-Pignatti C, De Stefano P, Barone F, et al: Penicillin compliance
Med 55:236, 1962. in splenectomized thalassemics. Eur J Pediatr 142:83, 1984.
316. Wasi P: Streptococcal infection leading to cardiac and renal involve- 344. Linet MS, Nyren O, Gridley G, et al: Causes of death among patients
ment in thalassaemia. Lancet 1:949, 1971. surviving at least one year following splenectomy. Am J Surg 172:320,
317. Cooper DM, Mansell AL, Weiner MA, et al: Low lung capacity and 1996.
hypoxemia in children with thalassemia major. Am Rev Respir Dis 345. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia major
121:639, 1980. in the UK: data from the UK Thalassaemia Register. Lancet 355:2051,
318. Secchi GC, Scotti PG, Cambiaghi G, et al: [Respiratory function tests 2000.
in adolescents with beta-thalassemia major (author’s transl)]. Haemato- 346. Angelucci E, Baronciani D: Allogeneic stem cell transplantation for
logica 67:23, 1982. thalassemia major. Haematologica 93:1780, 2008.
319. Hoyt RW, Scarpa N, Wilmott RW, et al: Pulmonary function abnor- 347. Lucarelli G, Galimberti M, Giardini C, et al: Bone marrow trans-
malities in homozygous beta-thalassemia. J Pediatr 109:452, 1986. plantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci
320. Keens TG, O’Neal MH, Ortega JA, et al: Pulmonary function 850:270, 1998.
abnormalities in thalassemia patients on a hypertransfusion program. 348. Sodani P, Gaziev D, Polchi P, et al: New approach for bone marrow
Pediatrics 65:1013, 1980. transplantation in patients with class 3 thalassemia aged younger than
321. Ooi GC, Khong PL, Lam WK, et al: Pulmonary iron overload in 17 years. Blood 104:1201, 2004.
thalassemia major presenting as small airway disease. Acta Haematol 349. Gaziev J, Sodani P, Polchi P, et al: Bone marrow transplantation in
108:43, 2002. adults with thalassemia: Treatment and long-term follow-up. Ann N Y
322. Cooper DM, Hyman CB, Weiler-Ravell D, et al: Gas exchange during Acad Sci 1054:196, 2005.
exercise in children with thalassemia major and Diamond-Blackfan 350. Gaziev D, Polchi P, Galimberti M, et al: Graft-versus-host disease after
anemia. Pediatr Res 19:1215, 1985. bone marrow transplantation for thalassemia: an analysis of incidence
323. Eldor A, Maclouf J, Lellouche F, et al: A chronic hypercoagulable state and risk factors. Transplantation 63:854, 1997.
and life-long platelet activation in beta thalassemia major. Southeast 351. Gaziev J, Marziali M, Isgrò A, et al: Bone marrow transplantation for
Asian J Trop Med Public Health 24:92, 1993. thalassemia from alternative related donors: improved outcomes with a
324. Rostagno C, Prisco D, Abbate R, et al: Pulmonary hypertension associ- new approach. Blood 122(15):2751–2756, 2013.
ated with long-standing thrombocytosis. Chest 99:1303, 1991. 352. Ley TJ, DeSimone J, Anagnou NP, et al: 5-azacytidine selectively
325. Fucharoen S, Youngchaiyud P, Wasi P: Hypoxaemia and the effect of increases gamma-globin synthesis in a patient with beta+ thalassemia.
aspirin in thalassaemia. Southeast Asian J Trop Med Public Health 12:90, N Engl J Med 307:1469, 1982.
1981. 353. Dunbar C, Travis W, Kan YW, et al: 5-Azacytidine treatment in a
326. Cappellini MD, Robbiolo L, Bottasso BM, et al: Venous thrombo- beta (0)-thalassaemic patient unable to be transfused due to multiple
embolism and hypercoagulability in splenectomized patients with alloantibodies. Br J Haematol 72:467, 1989.
thalassaemia intermedia. Br J Haematol 111:467, 2000. 354. Lowrey CH, Nienhuis AW: Brief report: treatment with azacitidine
327. Grossman H, Dische MR, Winchester PH, et al: Renal enlargement in of patients with end-stage beta-thalassemia. N Engl J Med 329:845,
thalassemia major. Radiology 100:645, 1971. 1993.